Pediatric Reference Intervals for Complete Blood Count Parameters in Healthy Turkish Infants and Children

Ünsal Özgen1, Filiz Orhon2, Gonca Keskindemirci3

  • 1Medical Faculty, Department of Pediatrics, Division of Pediatrics Hematology Oncology, Ondokuz Mayıs University, Samsun, Türkiye.

Insights

This study establishes crucial reference ranges for complete blood count (CBC) parameters in healthy Turkish children. These findings offer a vital resource for accurate pediatric hematological assessments nationwide.

Area of Science:

  • Pediatric Hematology
  • Clinical Pathology
  • Reference Range Establishment

Background:

  • Accurate reference ranges for complete blood count (CBC) parameters are essential for diagnosing and monitoring various pediatric health conditions.
  • Existing CBC reference ranges may not accurately reflect the diverse pediatric population in Türkiye.
  • Establishing region-specific reference intervals is critical for precise clinical interpretation.

Purpose of the Study:

  • To determine and provide comprehensive reference ranges for complete blood count (CBC) parameters in healthy children residing in Türkiye.
  • To establish age- and sex-stratified reference intervals for key hematological indicators.
  • To create a foundational dataset for improved pediatric hematological evaluations in Türkiye.

Main Methods:

  • A large cohort of 24,115 healthy children aged 1 month to 18 years were enrolled across 10 centers in Türkiye.
  • Complete blood count (CBC) measurements were systematically collected from participants attending Well Child Outpatient Clinics.
  • Data were analyzed to determine mean, median, and nonparametric reference intervals (2.5th-97.5th percentile) stratified by age and sex.

Main Results:

  • The study presents mean and median values for red blood cell, white blood cell, and platelet parameters across various pediatric age groups.
  • Nonparametrically determined CBC reference intervals (RIs) for the 2.5th to 97.5th percentile were provided, stratified by age and sex.
  • Detailed hematological data were compiled for a large, diverse population of healthy Turkish children.

Conclusions:

  • This research provides the first established reference ranges for hematological parameters specifically for Turkish children under 18 years of age.
  • The generated reference intervals offer a more reliable and accurate basis for hematological evaluations in pediatric healthcare across Türkiye.
  • These findings will support clinicians in the precise interpretation of CBC results, enhancing diagnostic accuracy and patient care.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
583
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
625
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
242